An evaluation of antiretroviral therapy associated with alpha-tocopherol supplementation in HIV-infected patients.

In HIV-infected patients, an increase in the production of oxygen-reactive species (ROS) is observed, with a consequent reduction of plasma levels of antioxidants such as alpha-tocopherol. The nuclear transcription factor-kappaB (NF-kappaB) is activated by a prooxidant state in the infected T cells through the release of its inhibitory subunit I-kappaB. The aim of the present work was to evaluate the behavior of hematological parameters and markers of anemia in HIV-infected patients who underwent antiretroviral therapy associated with 800 mg/day alpha-tocopherol supplementation. Blood samples were collected from supplemented (n=9) and not-supplemented (n=9) HIV-seropositive patients (n=18). We observed a decreased viral load in the alpha-tocopherol-supplemented group (p<0.05); other changes, such as an increase in the CD4/CD8 ratio, in the hematocrit and in the hemoglobin concentration were also observed, though lacking statistical significance. We conclude that antiretroviral therapy in association with alpha-tocopherol (800 mg/day) supplementation is more effective in reducing viral load levels and also, possibly, in recovering other hematological parameters after a 60-day period of use.

Prevalence of sorologic markers of HBV and HCV infection in HIV-1 seropositivr patients in Florionópolis, Brazil

B and C hepatitis are infections transmitted in ways similar to the human immunodeficiency virus (HIV). The present study was designed to assess the prevalence of hepatitis B (HBV) and hepatitis C (HCV) virus infection in HIV-1-infected patients who lived in the metropolitan areas of Florianópolis, in the State of Santa Catarina. Ninety-three patients seropositive to HIV-1 were identified by using enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence. Patients were assigned to according to HIV-1 transmission risk: homosexuals (n=20), heterosexuals (n=39), and intravenous drugs users (IVDU) (N=34). HbsAg, Anti-HBc, Anti-HBc IgM and Anti-HCV measurements were done using ELISA. HBV and HCV prevalence in HIV-1 infected patients was 71 percen and 53.8 percent, respectively. In the IVDU group, the prevalence of HBV (85.3 percent), of HCV (88.2 percent), and infections by both viruses (76.5 percent) was greater than that observed in the heterosexual and homosexual groups. Hepatitis B markers (HbsAg and Anti-HBc) for chronic persistent disease were recorded in 24.3 percent of patients, and for past infection in 71.2 of patients. The evidence of high prevalence of HBV and HCV infections in HIV-1 seropositive patients, mainly among intravenous drug users, should be included in educational programs in an effort to decrease the incidence of multiple infections.